SCHEMBL1749191

SCHEMBL1749191

COc1cc2c(-c3cc4cccnc4[nH]3)cn(C)c2cc1OCC(=O)Nc1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.62
MAPT P10636 6/20 0.47
GAA P10253 1/20 0.47
ESR2 Q92731 1/20 0.47
TSHR P16473 2/20 0.46
HSD17B10 Q99714 1/20 0.46
SYK P43405 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPK1 P28482 2/20 0.43
TP53 P04637 1/20 0.43
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 2/20 0.40
USP2 O75604 2/20 0.40
HTT P42858 2/20 0.40
HPGD P15428 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5795386 0.94 IGF1R (0.54) IGF1RMAPTGAAESR2TSHR
SCHEMBL1749017 0.85 IGF1R (0.70) IGF1RGAASYKMAPK1TP53
SCHEMBL1748773 0.82 IGF1R (0.66) IGF1RGAASYKMAPK1TP53
SCHEMBL1749103 0.82 IGF1R (0.80) IGF1RSYKRIPK1
SCHEMBL1748575 0.80 IGF1R (0.68) IGF1RMAPTGAATSHRHSD17B10
SCHEMBL1748771 0.80 IGF1R (0.75) IGF1RSYKRIPK1KDR
SCHEMBL1780899 0.79 IGF1R (1.00) IGF1RSYKRIPK1KDR
SCHEMBL1778539 0.78 IGF1R (0.90) IGF1RSYKRIPK1KDR
SCHEMBL1748786 0.77 IGF1R (0.83) IGF1RSYKRIPK1
SCHEMBL1748868 0.77 IGF1R (0.57) IGF1RSYKHTTRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US claimed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US claimed
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885MAPT 2220/4885GAA 3869/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885MAPT 2220/4885GAA 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.